Nexalin Technology Revenue

Nexalin Technology had revenue of $18.15K in the quarter ending September 30, 2025, a decrease of -49.63%. This brings the company's revenue in the last twelve months to $156.93K, down -3.18% year-over-year. In the year 2024, Nexalin Technology had annual revenue of $168.72K with 52.35% growth.

Revenue (ttm)

$156.93K

Revenue Growth

-3.18%

P/S Ratio

54.10

Revenue / Employee

$26,155

Employees

Market Cap

8.49M

Revenue Chart

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2024	168.72K	57.97K	52.35%
Dec 31, 2023	110.75K	-1.21M	-91.62%
Dec 31, 2022	1.32M	1.18M	817.20%
Dec 31, 2021	144.07K	-98.85K	-40.69%
Dec 31, 2020	242.91K	35.53K	17.13%
Dec 31, 2019	Pro	Pro	Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name	Revenue
Trinity Biotech	48.57M
Lifeward	24.50M
INVO Fertility	6.94M
Beyond Air	6.92M
Biomerica	4.46M
Intelligent Bio Solutions	3.58M
Tenon Medical	3.23M
Sintx Technologies	1.27M

Revenue Rankings

NXL News

13 days ago - Nexalin Announces Pivotal HALO™ Clarity Trial to Support Planned De Novo FDA Submission Targeting Multi-Billion-Dollar Insomnia Market - GlobeNewsWire
14 days ago - Nexalin Participates in and Commends Recent Congressional Momentum Supporting Deep Brain Neurostimulation Research for Veterans and Neurological Disorders - GlobeNewsWire
4 weeks ago - Nexalin Launches NeuroCare®, an AI-Driven Virtual Clinic Designed to Transform Access for Patients with Alzheimer's, Mood Disorders, TBI & PTSD Care - GlobeNewsWire
5 weeks ago - Nexalin Highlights its Expanding Body of Peer-Reviewed Neuroimaging Research Confirming its DIFS™ Technology as the Leader in Evidenced-Based Non-Invasive Brain Stimulation - GlobeNewsWire
7 weeks ago - Published Peer-Reviewed Study Demonstrates Nexalin's DIFS™ Neurostimulation Improves Attention and Normalizes Brain Activity in Patients with ADHD - GlobeNewsWire
3 months ago - Nexalin Technology Completes FDA Q-Submission Meeting for Gen-2 SYNC™ Neurostimulation Console in Alzheimer's Disease Program - GlobeNewsWire
3 months ago - Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on December 4 - GlobeNewsWire
3 months ago - Nexalin's 15 Milliamp Neurostimulation Device Demonstrates Promising Results in Treating Gambling Disorder with Alcohol Use Comorbidity - GlobeNewsWire

More News